US Stock MarketDetailed Quotes
SONN Sonnet BioTherapeutic
- 0.8600
- +0.0098+1.15%
Close Jul 26 16:00 ET
- 0.8401
- -0.0199-2.31%
Post 18:20 ET
4.49MMarket Cap0.31P/E (TTM)
0.8733High0.8200Low40.22KVolume0.8733Open0.8502Pre Close33.92KTurnover0.83%Turnover RatioLossP/E (Static)5.22MShares10.087052wk High1.47P/B4.18MFloat Cap0.820052wk Low--Dividend TTM4.86MShs Float41201.1600Historical High--Div YieldTTM6.27%Amplitude0.8200Historical Low0.8430Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
Sonnet BioTherapeutic Stock Forum
Sonnet Biotherapeutics Reports Encouraging Data From Phase 1B/2a Clinical Trial of Son-080 in Chemotherapy-Induced Peripheral Neuropathy (Cipn) That Support Advancement Into Phase 2 Study
Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain
Sonnet BioTherapeutics (NASDAQ:SONN) announced the development of two new immunotherapeutic drug candidates, SON-1411 and SON-1400, utilizing a modified IL-18 variant. SON-1411 combines IL-18BPR with IL-12 via Sonnet’s FHAB platform, while SON-1400 solely integrates IL-18BPR...
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
Sonnet BioTherapeutics (NASDAQ: SONN) announced the presentation of its SB221 study at the ASCO 2024 Annual Meeting. The study focuses on SON-1010, a recombinant human Interleukin-12 linked to Sonnet's albumin binding domain, in combination with atezolizumab (Tecentriq®). This Phase 1b/2a trial aims to evaluate the safety, tolerability, pharmacokinetics (PK), pharma...
NEWS
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
Sonnet BioTherapeutics (NASDAQ:SONN) has announced updated clinical data for its drug candidate SON-1010, used as a monotherapy or in combination with atezolizumab (Tecentriq®). The trials have enrolled a total of 61 subjects with dose escalation continuing in SB101 and SB221 trials. SON-1010 ...
The AACR Annual Meeting 2024 is scheduled to take place fromApril 5 to April 10, 2024at the San Diego Convention Center in San Diego, California1.This event is organized by the American Association for Cancer Research (AACR) and is a significant gathering for cancer researchers and other healthcare professionals1.Please check the official AACR website or contact the event organizers for the most accurate and up-to-date information1.
Accesswire· 1 min ago
Sonnet BioTherapeutics (NASDAQ: SONN), a biopharmaceutical company that specializes in developing innovative targeted biologic drugs, recently announced preliminary safety data from the ongoing Phase 1b/2a clinical trial of SON-080. This drug, which is being developed for the treatment of CIPN, met the study's initial pre-specified objective. This development could have s...
No comment yet